Skip to search formSkip to main contentSkip to account menu

Stanford V Regimen

Known as: Stanford V 
An abbreviation for a chemotherapy combination that is used to treat Hodgkin lymphoma and is being studied in the treatment of other types of cancer… 
National Institutes of Health

Related topics

Related topics

8 relations
Adult Hodgkin LymphomaBleomycinDoxorubicinEtoposide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
![Graphic][1] Introduction. Classical Hodgkin Lymphomas (cHL) include small numbers of malignant Reed-Sternberg (RS) cells… 
2011
2011
Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): Analysis from the phase III randomized U.S. Intergroup Trial E2496.
8035 Background: There remains a lack of prospective data studying ABVD or Stanford V in the modern era in advanced-stage elderly… 
2009
2009
Efficacy of Abbreviated Stanford V Chemotherapy and Involved Field Radiotherapy in Early Stage Hodgkin's Disease: Mature Results of the G4 Trial.
Abstract 1670 Poster Board I-696 The standard management for early stage Hodgkin9s disease (HD) is combined modality therapy. In… 
2008
2008
Randomised Comparison of the Stanford V (SV) Regimen and ABVD in the Treatment of Advanced Hodgkin Lymphoma (HL): Results from a UK NCRI Lymphoma Group Study, ISRCTN 64141244
Introduction: The weekly alternating SV regimen was compared to standard ABVD. An initial randomised phase II pilot study was… 
2007
2007
Treatment planning and delivery of involved field radiotherapy in advanced Hodgkin's disease: results from a questionnaire-based audit for the UK Stanford V regimen vs ABVD clinical trial quality…
This questionnaire forms the basis of the quality assurance (QA) programme for the UK randomized Phase III study of the Stanford… 
2006
2006
Incidence of secondary leukemia/myelodysplasia (AML/MDS) in Hodgkin's disease (HD) with three generations of therapy at Stanford University.
7516 Background: Long term HD survivors have an increased risk of therapy-related AML/MDS that peaks about 5 years (yr) after… 
2004
2004
Efficacy and Late Effects of Stanford V Chemotherapy and Radiotherapy in Untreated Hodgkin’s Disease: Mature Data in Early and Advanced Stage Patients.
From 5/89 to 5/01, 256 patients (pts) with classical Hodgkin’s disease were treated on prospective trials with the weekly… 
2001
2001
Treatment of refractory hodgkin’s disease with modified stanford V program
This study analyzes the results using an Stanford V modified program in the treatment of refractory Hodgkin’s disease (RHD). We… 
Review
1999
Review
1999
Treatment of advanced Hodgkin's lymphoma: standard and experimental approaches.
The introduction of polychemotherapy and improved radiation techniques has transformed Hodgkin's lymphoma from an incurable… 
Highly Cited
1982
Highly Cited
1982
Reproductive, perinatal, and environmental factors as predictors of the cognitive and language development of preterm and full-term infants.
The accuracy of a risk index based on reproductive and demographic factors to predict subsequent development was tested with 51… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)